

Orchard Therapeutics plc  
108 Cannon Street  
London EC4N 6EU  
United Kingdom

April 27, 2022

**Via EDGAR Transmission**

United States Securities and Exchange Commission  
Division of Corporation Finance  
100 F Street, N.E.  
Washington, D.C. 20549

Re: Orchard Therapeutics plc: Registration Statement on Form S-3, filed March 30, 2022 (File No. 333-263967)

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “**Act**”), Orchard Therapeutics plc (the “**Company**”) hereby requests that the effective date of the above-referenced registration statement, as amended (the “**Registration Statement**”) be accelerated to April 29, 2022, at 4:01 p.m. Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.

If you have any questions regarding this request, please contact Benjamin K. Marsh of Goodwin Procter LLP at (212) 813-8816.

Sincerely,  
Orchard Therapeutics plc

/s/ Frank E. Thomas

---

Frank E. Thomas  
President and Chief Operating Officer

cc: Bobby Gaspar, M.D., Ph.D., *Chief Executive Officer, Orchard Therapeutics plc*  
Christopher York, *Corporate Counsel, Orchard Therapeutics plc*